1 Introduction

Helicobacter pylori (H. pylori) is a Gram negative, spiral-shaped microbe that colonizes the stomach and has become a major public health concern, with more than half of the world’s population affected by it (1, 2). It is a widely accepted notion that H. pylori infection is correlated with a range of gastrointestinal ailments, including chronic gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric cancer. In the past few years, numerous studies have revealed that H. pylori infection is not only the cause of gastrointestinal issues, but could also be associated with a variety of extragastrointestinal illnesses including cardiovascular, hematological, neurological, metabolic, and skin diseases (3–5). By eliminating H. pylori in its initial stages, the chances of developing gastric cancer can be significantly reduced (6, 7).

In the past, standard triple therapy (STT), which was made up of a proton pump inhibitor (PPI) and two antibiotics (amoxicillin and clarithromycin/metronidazole), was the most common approach to eradicating H. pylori. However, the growing prevalence of antibiotic resistance has complicated attempts to eradicate H. pylori, particularly with regards to clarithromycin resistance, and thus clarithromycin triple therapy may no longer be the most suitable first-line treatment (3, 8). Currently, the bismuth quadruple therapy (BQT) for 10–14 days is first-line treatment that are recommended in several guidelines and consensus reports (3, 9–11). Although BQT is an effective method for eradicating H. pylori infection, adverse events and poor compliance during the eradication process are common (12, 13). Additionally, increasing evidence points to the fact that eradication drugs, especially antibiotics and PPI, can cause an imbalance in the gut microbiota, which has a significant impact on human health (14, 15). Therefore, new therapies are needed.

Probiotics, as living microorganisms, have been employed extensively to treat illnesses like antibiotic-induced diarrhea, colitis, and metabolic syndrome (16). Saccharomyces boulardii (S. boulardii) is the only probiotic preparation derived from fungi that is used worldwide. A meta-analysis by Szajewska et al. (17) demonstrated that the supplementation of S. boulardii in the STT for H. pylori can result in a higher eradication rate and a lower incidence of side effects. The resistance to antibiotics has increased significantly, making STT no longer as effective as before. It remains uncertain if the addition of S. boulardii to BQT recommended in the current guidelines can enhance the H. pylori eradication rate and decrease the incidence of adverse events. Several randomized controlled trials (RCTs) have been conducted on this topic in recent years, yet the small sample size of each study has not allowed for any definite conclusions to be made. To evaluate the efficacy and safety of S. boulardii assisted BQT versus BQT, we therefore performed this systematic review and meta-analysis.

2 Materials and methods

This systematic review was conducted in accordance with the PRISMA 2020 statement (18). The protocol of this study was registered in the Open Science Framework.

2.1 Literature search

Utilizing pre-determined search terms, we performed systematic searches in PubMed, Embase, Web of Science, and the Cochrane library database, up to November 1, 2023, without any language limitations. The search terms included “helicobacter pylori,” “H. pylori,” helicobacter, “campylobacter pylori,” “saccharomyces boulardii,” “S. boulardii,” probiotics, probiotic, “bismuth.” Taking PubMed as an example, the detailed search strategy was follow: (“helicobacter”[MeSH Terms] OR “helicobacter”[tiab] OR “helicobacter pylori”[MeSH Terms] OR “helicobacter pylori”[tiab] OR “H. pylori”[tiab] OR “campylobacter pylori”[tiab]) AND (“saccharomyces boulardii”[tiab] OR “S. boulardii”[tiab] OR probiotics[MeSH] OR probiotics[tiab] OR probiotic[tiab]) AND (“bismuth”[MeSH Terms] OR “bismuth”[tiab]). The retrieval strategies for the other three electronic databases are detailed in Supplementary Table S1. Additionally, we examined the reference lists of the evaluated studies to identify any further eligible studies.

2.2 Study selection

Two reviewers (Chen Y and Teng T) independently conducted two screenings of the study selection. They initially evaluated the title and abstract of the articles and excluded those that were unlikely to be related to the research. Then, the two reviewers examined the full-text articles and chose those that were eligible for meta-analysis.

Studies that fulfilled the following criteria were included: (1) Study design: RCTs; (2) Participants: adults patients who have not had any professional treatment for H. pylori in the past; (3) Intervention: Combined treatment of S. boulardii with BQT; (4) Comparison: the same BQT (bismuth + PPI + two antibiotics); and (5) Outcomes: H. pylori eradication rate and the incidence of adverse events (including the overall and specific adverse events). We will not consider studies on other probiotics, duplicates, Non-RCTs, animal experiments, reviews and meta-analysis, conference abstracts, letters, editorials, guidelines and consensus, and studies from which data cannot be gathered.

2.3 Data extraction and risk of bias

The data collected from the eligible studies included the name of the first author, year of publication, country of origin, sample size, diagnosis methods used for H. pylori, information regarding the intervention and control groups, and relevant data on the outcomes of interest.

We utilized the revised Cochrane Risk of Bias Tool (RoB 2.0) for randomized trials to assess the risk of bias in the included studies, encompassing the following five domains: (1) bias arising during randomization; (2) bias due to deviations from intended interventions; (3) bias from missing outcome data; (4) bias in outcome measurement; and (5) bias in reporting outcome selection. The bias risk in each category can be categorized into three levels: low risk of bias, some concerns, and high risk of bias (19). Two reviewers (Chen Y and Teng T) independently collected data and assessed the risk of bias for each study, and any disagreements were resolved through consensus.

2.4 Statistical analysis

The relative risk (RR) and 95% confidence intervals (CIs) were calculated as summary effect size following the random-effects model. To assess the heterogeneity between studies, both the I2 statistic and the chi-square test with a p value <0.10 were employed. If the p value was <0.10, substantial heterogeneity was determined. Heterogeneity was categorized as insignificant, low, moderate, or high, depending on the I2 values, which were 0–25%, 26–50%, 51–75%, and above 75%, respectively (20). Data for H. pylori eradication rate were analyzed using both intention-to-treat (ITT) and per-protocol (PP) analysis. The ITT analysis involved all participants who were initially assigned to the group through random selection. The PP analysis excluded patients who did not withdraw for any reason and received treatment doses below 90%. We performed pre-specified subgroup analyses by duration of BQT, dosage of S. boulardii and duration of supplementation with S. boulardii. Subgroup analyses of H. pylori eradication rate were conducted through ITT analysis. The publication bias should be investigated by funnel plot and Egger test if at least 10 studies are included in the meta-analysis (21, 22). It was determined that a p-value of less than 0.05 was indicative of a significant publication bias. All analyses were conducted using the RevMan 5.3 software (the Cochrane Collaboration, Copenhagen, Denmark) and STATA/SE (Version 12.0, STATA Corporation, Texas, United States).

3 Results 3.1 Study selection

System retrieval produced 470 records, of which 208 were duplicates, leaving 262 records. After screening titles and abstracts, 234 records were excluded, leaving 28 full-text articles to be reviewed. Ultimately, 6 RCTs (8 intervention arms) (23–28) were included in the meta-analysis, as illustrated in Figure 1.

Figure 1. PRISMA flowchart of study selection process.

3.2 Study characteristics

A total of six RCTs (involving 1,404 patients) published from 2017 to 2023 included in our meta-analysis. All studies originate from Asia, five of which are from China (23–26, 28) and one from Iran (27). Of all the studies, one was a multicenter RCT (26), while the remaining five were single center RCTs. Two RCTs (23, 25) included multiple arms. The number of participants in these RCTs varied from 104 to 348. Regarding the duration of treatment for BQT, there were three studies (23–25) with a duration of 10 days and the other three studies (26–28) with a duration of 14 days. The dosage of S. boulardii varied between studies, with one study (27) using 500 mg/day and the others 1,000 mg/day (23–26, 28). The duration of S. boulardii regimen was 14 or 28 days in one study, while the other five studies only had 14 days of treatment. The major characteristics of the studies incorporated are outlined in Table 1.

Table 1. Main characteristics of included studies.

3.3 Risk of bias

All of the six RCTs included in the analysis exhibited a low risk of bias in terms of the randomization process, missing outcome data, measurement of the outcome, and selection of reported results. In relation to bias from deviations in the intended intervention, five studies were deemed to have some concerns, while one study was judged to have a low risk. The details of the risk of bias are presented in Supplementary Figures S1, S2.

3.4 Helicobacter pylori eradication rate

Six RCTs with 1,404 participants reported data on the H. pylori eradication rate. The results of the ITT analysis showed that the combination of S. boulardii with BQT had a higher eradication rate than BQT alone (87.0% versus 83.3%), with a pooled RR of 1.05 (95% CI: 1.00–1.10, p = 0.03) and no heterogeneity (I2 = 0%, p = 0.95) (Figure 2). In the PP analysis, the eradication rate of S. boulardii in combination with BQT was higher than BQT alone (93.7% versus 91.0%), however, there was no statistical significance between the two groups (RR = 1.03, 95% CI: 1.00–1.06, p = 0.07) (Figure 3). No statistical heterogeneity was observed (I2 = 0%, p = 0.90).

Figure 2. Forest plot of the H. pylori eradication rate (ITT data).

Figure 3. Forest plot of the H. pylori eradication rate (PP data).

Based on ITT analysis data, we further conducted subgroup analyses based on duration of BQT regimen, dosages of S. boulardii, and duration of S. boulardii to explore the potential influencing factor on the overall results. Results from the subgroup analysis based on duration of BQT regimen showed that the H. pylori eradication rate was higher in the S. boulardii supplementation group in the 10-day subgroup (n = 3 RCTs, RR = 1.06, 95% CI: 0.99–1.13, p = 0.11) and 14-day subgroup (n = 3 RCTs, RR = 1.04, 95% CI: 0.99–1.10, p = 0.15), yet the difference was not statistically significant. Results from the subgroup analysis based on dosages of S. boulardii showed that the H. pylori eradication rate was higher in the S. boulardii supplementation group in the subgroup of 500 mg/day (n = 1 RCT, RR = 1.09, 95% CI: 0.96–1.24, p = 0.19) and the subgroup of 1,000 mg/day (n = 5 RCTs, RR = 1.04, 95% CI: 1.00–1.09, p = 0.07), yet the difference was not statistically significant. In a subgroup analysis based on duration of S. boulardii, the H. pylori eradication rate increased significantly in the 14-day subgroup (n = 6 RCTs, RR = 1.05, 95% CI: 1.00–1.09, p = 0.04), but not in the 28-day subgroup (n = 1 RCT, RR = 1.09, 95% CI: 0.95–1.25, p = 0.20). The results of subgroup analyses were summarized in Table 2.

Table 2. Results of subgroup analyses of H. pylori eradication rate (ITT data).

3.5 Adverse events

Four RCTs (23–26) involving a total of 1,128 participants revealed the incidence of overall adverse events. Results of the meta-analysis showed that the combination of S. boulardii and BQT had a significantly lower rate of overall adverse events than BQT alone (22% vs. 39%, RR = 0.56, 95% CI: 0.44–0.70, p < 0.00001). The heterogeneity was low (I2 = 38, p = 0.18) (Figure 4).

Figure 4. Forest plot of the overall adverse events.

When it comes to specific adverse events, the results from the meta-analysis showed that those in the S. boulardii combined BQT group experienced a lower rate of diarrhea (n = 5 RCTs, 7.9% vs. 25.7%, RR = 0.29, 95% CI: 0.17–0.48, p < 0.00001), constipation (n = 3 RCTs, 2.9% vs. 8.4%, RR = 0.35, 95% CI: 0.14–0.88, p = 0.03) and abdominal distention (n = 4 RCTs, 4.9% vs. 12.7%, RR = 0.41, 95% CI: 0.23–0.72, p = 0.002) than the BQT group. Nonetheless, no significant difference was seen between the two groups in regards to nausea, vomiting, abdominal pain, rash and dizzy. The results of adverse events were presented in Figures 5, 6.

Figure 5. Forest plot of the specific adverse events (diarrhea, nausea, vomiting, abdominal pain, and abdominal distention).

Figure 6. Forest plot of the specific adverse events (constipation, rash, and dizzy).

4 Discussion 4.1 Main findings and potential explanations

To our knowledge, this is the first time that a meta-analysis has been conducted to explore the effects of combining S. boulardii with BQT for the eradication of H. pylori compared to BQT alone. In this meta-analysis of six RCTs with 1,404 participants, we demonstrated that, when analyzed by ITT or PP, the eradication rate of the S. boulardii-supplemented BQT group was higher than that of the single BQT group. However, in PP analysis, there was no statistically significant difference between the two groups. It is worth noting that the 95% CI for both ITT and PP analyses overlapped with the invalid line, which could be due to the sample size being too small to draw statistically significant conclusions, or the high eradication rate of BQT, making it difficult to see the effects of adding S. Boulardii. In order to explore the effect of different durations of BQT regimen, different dosages and durations of S. boulardii on the overall results, we conducted subgroup analyses. The results showed that, although the eradication rate of H. pylori in the group supplemented with S. boulardii was higher than that in the single BQT group, except for the subgroup that was treated with S. boulardii for 14 days, there was no statistically significant difference between the two groups in the other subgroups. With such a small number of studies included in these subgroups, it may be difficult to draw statistically significant conclusions. Our meta-analysis also demonstrated that taking S. boulardii can reduce the occurrence of overall adverse events, diarrhea, abdominal distention, and constipation while eradicating H. pylori.

Saccharomyces boulardii, a fungal probiotic preparation, was originally isolated from tropical fruit peels. It is stable over a wide pH range, including acidic conditions and temperature levels, as well as during contact with bile salts and gastrointestinal enzymes (29). Due to its natural properties, the fungus is impervious to the antibiotic. Furthermore, the introduction of S. boulardii CNCM I-745 cannot generate antibiotic resistance since the exchange of antibiotic resistance genes with bacteria is improbable (30, 31). Evidence from current studies suggests that S. boulardii can successfully combat H. pylori infection both in vitro and in vivo. S. boulardii has the ability to directly inhibit H. pylori through the production of lactic acid, short-chain fatty acids, bacteritin, hydrogen peroxide, neuraminidase, and other substances (28). Furthermore, compared to other probiotic bacterial strains, S. boulardii has a much larger volume, resulting in a greater surface area and improved ability to adhere to pathogenic bacteria, thus impacting the colonization of H. pylori in the gastric mucosa (32). S. boulardii has neuraminidase activity that is specific to alpha (2–3)-linked sialic acid, and it acts by attaching itself to the adhesin of H. pylori, thereby preventing the adhesion of H. pylori in the duodenum (33). Moreover, S. boulardii can promote immunoprotection by triggering the secretion of sIgA and immunoglobulin in the gastrointestinal tract (34). Additionally, S. boulardii has an impact on the gut microbiota, thus decreasing gastrointestinal issues in patients (35), which leads to increased compliance and, as a result, a higher eradication rate of H. pylori.

4.2 Comparison with previous work

Previously, Yao et al. (36) conducted a meta-analysis of 10 RCTs and explored the effect of probiotic-supplemented BQT for the treatment of H. pylori. The results of the meta-analysis indicated that the eradication rate of the probiotic-supplemented BQT group was higher than that of the BQT group alone in both ITT (RR = 1.07, 95% CI: 1.02–1.11, p = 0.003) and PP analyses (RR = 1.04, 95% CI: 1.00–1.07, p = 0.03). In addition, probiotic supplementation was associated with a lower rate of side effects, diarrhea, and a bitter taste. Nevertheless, the meta-analysis included different probiotics, with only one study using S. Boulardii, which may lead to an inaccurate conclusion due to the strain specificity of probiotics and the fact that not all probiotics improve the H. pylori eradication rate or reduce the incidence of side effects (37). In comparison to the prior meta-analyses, our meta-analysis was more reliable due to the fact that it only focused on a particular probiotic strain (S. Boulardii) for consolidation.

4.3 Strengths and limitations

This meta-analysis has the major advantage of providing the latest and most comprehensive data on the impact of utilizing a single probiotic strain (S. boulardii) in combination with BQT to evaluate the eradication of H. pylori compared to BQT. In addition, we employed a rigorous systematic review methodology, employing a comprehensive search strategy, explicit inclusion and exclusion criteria, strict quality assessment, and strictly adhering to PRISMA statement for reporting, all of which ensured our results were transparent and reliable.

Despite this, this study still has certain limitations. First, out of all the studies we included, only one was a placebo-controlled double-blind trial, while the others did not include placebos. The blinding method and allocation were unclear, which could have an impact on our subjective outcome indicators (e.g., incidence of adverse events). Therefore, in the future, it is necessary to further conduct high-quality, placebo-controlled, double-blind trials to further verify these findings. Second, subgroup analyses only involve limited data, which can make it difficult to identify significant differences. Third, with the limited data available, it is difficult to ascertain the ideal dosage and duration of S. boulardii to achieve the desired results. Further optimization and confirmation is needed through further research. Fourth, this study did not include the classic BQT, currently recommended by international guidelines, that consists of PPI, salt of bismuth, tetracycline and metronidazole. Further exploration of this limitation is necessary in future research. Additionally, as there were less than 10 studies included, further publication bias testing was not conducted. Nevertheless, the potential for bias cannot be entirely dismissed. Finally, our meta-analysis focused on Asian populations, thus the results of this study can be applied only to the Asian population, and further research is required to determine if the findings can be extended to other populations.

5 Conclusion

Current evidence suggests that supplementation with S. boulardii in BQT may not have a major effect on the H. pylori eradication rate, but significantly reduces the incidence of overall adverse events, diarrhea, abdominal distention and constipation. Combining S. Boulardii with BQT can help alleviate symptoms, potentially improving patient adherence and offering a valuable treatment option.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

YC: Writing – original draft, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization. TT: Formal analysis, Methodology, Validation, Writing – original draft. YS: Data curation, Methodology, Validation, Writing – original draft. W-ZC: Conceptualization, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2024.1344702/full#supplementary-material

Footnotes References

1. Shirani, M, Pakzad, R, Haddadi, MH, Akrami, S, Asadi, A, Kazemian, H, et al. The global prevalence of gastric cancer in Helicobacter pylori-infected individuals: a systematic review and meta-analysis. BMC Infect Dis. (2023) 23:543. doi: 10.1186/s12879-023-08504-5

PubMed Abstract | Crossref Full Text | Google Scholar

2. Hooi, JKY, Lai, WY, Ng, WK, Suen, MMY, Underwood, FE, Tanyingoh, D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. (2017) 153:420–9. doi: 10.1053/j.gastro.2017.04.022

Crossref Full Text | Google Scholar

3. Malfertheiner, P, Megraud, F, Rokkas, T, Gisbert, JP, Liou, JM, Schulz, C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. (2022):gutjnl-2022-327745. doi: 10.1136/gutjnl-2022-327745

Crossref Full Text | Google Scholar

4. Sun, Q, Yuan, C, Zhou, S, Lu, J, Zeng, M, Cai, X, et al. Helicobacter pylori infection: a dynamic process from diagnosis to treatment. Front Cell Infect Microbiol. (2023) 13:1257817. doi: 10.3389/fcimb.2023.1257817

PubMed Abstract | Crossref Full Text | Google Scholar

5. Pellicano, R, Ianiro, G, Fagoonee, S, Settanni, CR, and Gasbarrini, A. Review: extragastric diseases and Helicobacter pylori. Helicobacter. (2020) 25:e12741. doi: 10.1111/hel.12741

Crossref Full Text | Google Scholar

6. Lee, YC, Chiang, TH, Chou, CK, Tu, YK, Liao, WC, Wu, MS, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and Meta-analysis. Gastroenterology. (2016) 150:1113–1124.e5. doi: 10.1053/j.gastro.2016.01.028

PubMed Abstract | Crossref Full Text | Google Scholar

7. Ford, AC, Forman, D, Hunt, RH, Yuan, Y, and Moayyedi, P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. (2014) 348:g3174. doi: 10.1136/bmj.g3174

PubMed Abstract | Crossref Full Text | Google Scholar

8. Liu, WZ, Xie, Y, Lu, H, Cheng, H, Zeng, ZR, Zhou, LY, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. (2018) 23:e12475. doi: 10.1111/hel.12475

PubMed Abstract | Crossref Full Text | Google Scholar

9. Fallone, CA, Chiba, N, van Zanten, SV, Fischbach, L, Gisbert, JP, Hunt, RH, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. (2016) 151:51–69.e14. doi: 10.1053/j.gastro.2016.04.006

Crossref Full Text | Google Scholar

10. Zhou, L, Lu, H, Song, Z, Lyu, B, Chen, Y, Wang, J, et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J. (2022) 135:2899–910. doi: 10.1097/CM9.0000000000002546

PubMed Abstract | Crossref Full Text | Google Scholar

11. Leung, WK, Cheung, KS, Sham, PCO, Tang, RSY, Loo, CK, Hsu, ASJ, et al. Consensus recommendations for the screening, diagnosis, and management of Helicobacter pylori infection in Hong Kong. Hong Kong Med J. (2023) 29:532–41. doi: 10.12809/hkmj2210321

PubMed Abstract | Crossref Full Text | Google Scholar

12. Liou, JM, Fang, YJ, Chen, CC, Bair, MJ, Chang, CY, Lee, YC, et al. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. (2016) 388:2355–65. doi: 10.1016/S0140-6736(16)31409-X

PubMed Abstract | Crossref Full Text | Google Scholar

13. Yang, J, Zhang, Y, Fan, L, Zhu, YJ, Wang, TY, Wang, XW, et al. Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori. Am J Gastroenterol. (2019) 114:437–45. doi: 10.14309/ajg.0000000000000132

PubMed Abstract | Crossref Full Text | Google Scholar

14. Ye, Q, Shao, X, Shen, R, Chen, D, and Shen, J. Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: a systematic review and meta-analysis. Helicobacter. (2020) 25:e12713. doi: 10.1111/hel.12713

PubMed Abstract | Crossref Full Text | Google Scholar

15. Tao, ZH, Han, JX, and Fang, JY. Helicobacter pylori infection and eradication: exploring their impacts on the gastrointestinal microbiota. Helicobacter. (2020) 25:e12754. doi: 10.1111/hel.12754

Crossref Full Text | Google Scholar

16. He, C, Xie, Y, Zhu, Y, Zhuang, K, Huo, L, Yu, Y, et al. Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: a multicenter randomized double-blind placebo-controlled trial. Front Immunol. (2022) 13:1033063. doi: 10.3389/fimmu.2022.1033063

PubMed Abstract | Crossref Full Text | Google Scholar

17. Szajewska, H, Horvath, A, and Kołodziej, M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. (2015) 41:1237–45. doi: 10.1111/apt.13214

PubMed Abstract | Crossref Full Text | Google Scholar

18. Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) 372:n71. doi: 10.1136/bmj.n71

Crossref Full Text | Google Scholar

19. Sterne, JAC, Savović, J, Page, MJ, Elbers, RG, Blencowe, NS, Boutron, I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. (2019) 366:l4898. doi: 10.1136/bmj.l4898

Crossref Full Text | Google Scholar

21. Sterne, JA, and Egger, M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. (2001) 54:1046–55. doi: 10.1016/s0895-4356(01)00377-8

Crossref Full Text | Google Scholar

22. Higgins, JPT, Thomas, J, Chandler, J, Cumpston, M, Li, T, Page, MJ, et al. eds. Cochrane handbook for systematic reviews of interventions version 6.4 (updated 2023). Cochrane: (2023) Available at: www.training.cochrane.org/handbook.

Google Scholar

23. Zhu, XY, Du, J, Wu, J, Zhao, LW, Meng, X, and Liu, GF. Influence of Saccharomyces boulardii sachets combined with bismuth quadruple therapy for initial Helicobacter pylori eradication. Zhonghua Yi Xue Za Zhi. (2017) 97:2353–6. doi: 10.3760/cma.j.issn.0376-2491.2017.30.008

PubMed Abstract | Crossref Full Text | Google Scholar

24. Zhu, XY, Du, J, Zhao, WJ, Wu, J, Zhao, LW, Meng, X, et al. Influence of two kinds of probiotics combined with bismuth quadruple therapy for Helicobacter pylori eradication. Zhonghua Yi Xue Za Zhi. (2018) 98:2246–9. doi: 10.3760/cma.j.issn.0376-2491.2018.28.007

PubMed Abstract | Crossref Full Text | Google Scholar

25. He, CX, Kong, FT, Liang, F, Wang, KX, Li, H, Liu, YL, et al. Influence of different timing of Saccharomyces boulardii combined with bismuth quadruple therapy for Helicobacter pylori eradication. Zhonghua Yi Xue Za Zhi. (2019) 99:1731–4. doi: 10.3760/cma.j.issn.0376-2491.2019.22.010

PubMed Abstract | Crossref Full Text | Google Scholar

26. Zhao, Y, Yang, Y, Aruna,, Xiao, J, Song, J, Huang, T, et al. Saccharomyces boulardii combined with quadruple therapy for Helicobacter pylori eradication decreased the duration and severity of diarrhea: a multi-center prospective randomized controlled trial. Front Med (Lausanne). (2021) 8:776955. doi: 10.3389/fmed.2021.776955

Crossref Full Text | Google Scholar

27. Naghibzadeh, N, Salmani, F, Nomiri, S, and Tavakoli, T. Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial. BMC Gastroenterol. (2022) 22:107. doi: 10.1186/s12876-022-02187-z

PubMed Abstract | Crossref Full Text | Google Scholar

28. He, XJ, Wang, XL, Sun, DJ, Huang, XY, Liu, G, Li, DZ, et al. The efficacy and safety of Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication: a single-center, prospective randomized-control study. Ther Adv Gastroenterol. (2023) 16:17562848221147763. doi: 10.1177/17562848221147763

Crossref Full Text | Google Scholar

29. Kaźmierczak-Siedlecka, K, Ruszkowski, J, Fic, M, Folwarski, M, and Makarewicz, W. Saccharomyces boulardii CNCM I-745: a non-bacterial microorganism used as probiotic agent in supporting treatment of selected diseases. Curr Microbiol. (2020) 77:1987–96. doi: 10.1007/s00284-020-02053-9

PubMed Abstract | Crossref Full Text | Google Scholar

30. Neut, C, Mahieux, S, and Dubreuil, LJ. Antibiotic susceptibility of probiotic strains: is it reasonable to combine probiotics with antibiotics? Med Mal Infect. (2017) 47:477–83. doi: 10.1016/j.medmal.2017.07.001

Crossref Full Text | Google Scholar

31. Moré, MI, and Swidsinski, A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a review. Clin Exp Gastroenterol. (2015) 8:237–55. doi: 10.2147/CEG.S85574

PubMed Abstract | Crossref Full Text | Google Scholar

32. Czerucka, D, Piche, T, and Rampal, P. Review article: yeast as probiotics –Saccharomyces boulardii. Aliment Pharmacol Ther. (2007) 26:767–78. doi: 10.1111/j.1365-2036.2007.03442.x

Crossref Full Text | Google Scholar

33. Sakarya, S, and Gunay, N. Saccharomyces boulardii expresses neuraminidase activity selective for α2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS. (2014) 122:941–50. doi: 10.1111/apm.12237

PubMed Abstract | Crossref Full Text | Google Scholar

34. Buts, JP, Bernasconi, P, Vaerman, JP, and Dive, C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci. (1990) 35:251–6. doi: 10.1007/BF01536771

PubMed Abstract | Crossref Full Text | Google Scholar

35. Cárdenas, PA, Garcés, D, Prado-Vivar, B, Flores, N, Fornasini, M, Cohen, H, et al. Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome. Eur J Clin Microbiol Infect Dis. (2020) 39:1365–72. doi: 10.1007/s10096-020-03854-3

PubMed Abstract | Crossref Full Text | Google Scholar

36. Yao, G, Fan, X, and Lu, D. Efficacy and safety of probiotic-supplemented bismuth quadruple therapy for the treatment of Helicobacter pylori infection: a systematic review and meta-analysis. J Int Med Res. (2023) 51:3000605231203841. doi: 10.1177/03000605231203841

PubMed Abstract | Crossref Full Text | Google Scholar

37. McFarland, LV, Huang, Y, Wang, L, and Malfertheiner, P. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterol J. (2016) 4:546–61. doi: 10.1177/2050640615617358

PubMed Abstract | Crossref Full Text | Google Scholar